Hereditary Ovarian Cancer-Assessing Risk and Prevention Strategies

Obstetrics and Gynecology Clinics of North America

Volumn 34, Issue 4, 2007, Pages 651-665

  Pavelka, James C ^a,b   Li, Andrew J ^a,b   Karlan, Beth Y ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT;

BREAST CANCER; CANCER PREVENTION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DISEASE PREDISPOSITION; DNA STRAND BREAKAGE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; MISMATCH REPAIR; ONCOGENE; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS; OVARIECTOMY; RISK ASSESSMENT; RISK FACTORS;

EID: 36549066243     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2007.09.005     Document Type: Review

References (50)

1. Rubin S.C.M., Blackwood M.A., Bandera C.M., et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178 (1998) 670-675
2. Reedy M., Gallion H., Fowler J.M., et al. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 85 (2002) 255-259
3. Gudmundsdottir K., and Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25 43 (2006) 5864-5874
4. King M.-C., Marks J.H., Mandell J.B., and for The New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
5. Risch H.A., McLaughlin J.R., Cole D.E.C., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68 (2001) 700-710
6. Whittemore A.S., Gong G., and Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case- control studies of ovarian cancer. Am J Hum Genet 60 (1997) 496-504
7. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 (1997) 1401-1408
8. Moslehi R., Chu W., Karlan B., et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66 (2000) 1259-1272
9. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91 (1999) 1310-1316
10. Weitzel J.N., Lagos V.I., Cullinane C.A., et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 297 23 (2007) 2587-2595
11. Freedman A.N., Seminara D., Gail M.H., et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 97 10 (2005) 715-723
12. Szabo C.I., and King M.C. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60 (1997) 1013-1020
13. Payne S.R., Newman B., and King M.C. Complex germline rearrangement of BRCA1 associated with breast and ovarian cancer. Genes Chromosomes Cancer 29 1 (2000) 58-62
14. Lynch H.T., Snyder C., Lynch J.F., et al. Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 165 2 (2006) 91-97
15. Scheuer L., Kauff N., Robson M., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 5 (2002) 1260-1268
16. Liede A., Karlan B.Y., Baldwin R.L., et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20 6 (2002) 1570-1577
17. Gaarenstroom K.N., van der Hiel B., Tollenaar R.A., et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 16 Suppl 1 (2006) 54-59
18. National Comprehensive Cancer Network clinical practice guidelines in oncology, genetic/familial high risk assessment: breast and ovarian. V.I. 2007. Available at: www.nccn.org. Accessed September 1, 2007.
19. Goff B.A., Mandel L.S., Melancon C.H., et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291 22 (2004) 2705-2712
20. Narod S.A., Risch H., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339 7 (1998) 424-428
21. Modan B., Hartge P., Hirsh-Yechezkel G., et al., National Israel Ovarian Cancer Study Group. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345 4 (2001) 235-240
22. McLaughlin J.R., Risch H.A., Lubinski J., et al., Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8 1 (2007) 26-34
23. Narod S.A., Dube M.P., Klijn J., et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94 23 (2002) 1773-1779
24. Lynch H.T., Lemon S.J., Durham C., et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer 79 (1997) 2219-2228
25. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (2002) 1609-1615
26. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (2002) 1616-1622
27. Ford D., Easton D.F., Bishop D.T., et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343 (1994) 692-695
28. Rebbeck T.R., Friebel T., Wagner T., et al., PROSE Study Group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23 31 (2005) 7804-7810 Epub 2005 Oct 11
29. Paley P.J., Swisher E.M., Garcia R.L., et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 80 (2001) 176-180
30. Colgan T.J., Boerner S.L., Murphy J., et al. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 85 (2002) 397-403
31. Colgan T.J., Murphy J., Cole D.E., et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25 (2001) 1283-1289
32. Powell C.B., Kenley E., Chen L.-M., et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23 (2005) 127-132
33. Medeiros F., Muto M.G., Lee Y., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30 (2006) 230-236
34. Finch A., Beiner M., Lubinski J., et al., Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296 (2006) 185-192
35. Piver M.S., Jishi M.F., Tsukada Y., et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71 (1993) 2751-2755
36. Lu K.H., Garber J.E., Cramer D.W., et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18 (2000) 2728-2732
37. Chen K.T., Schooley J.L., and Flam M.S. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 66 (1985) 93S-104S
38. Stratton J.F., Gayther S.A., Russell P., et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 336 (1997) 1125-1130
39. Lavie O., Hornreich G., Ben Arie A., et al. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 96 (2000) 28-32
40. Levine D.A., Lin O., Barakat R.R., et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 80 (2001) 395-398
41. Zweemer R.P., van Diest P.J., Verheijen R.H., et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 76 (2000) 45-50
42. Aziz S., Kuperstein G., Rosen B., et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Obstet 80 (2001) 341-345
43. Boyd J., Sonoda Y., Federici M.G., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283 17 (2000) 2260-2265
44. Cass I., Baldwin R.L., Varkey T., et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97 9 (2003) 2187-2195
45. Cortez D., Wang Y., Qin J., et al. Requirement of ATM dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks. Science 286 (1999) 1162-1166
46. Watson P., Butzow R., Lynch H.T., et al., International Collaborative Group on HNPCC. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 82 2 (2001) 223-228
47. Rijcken F.E., Mourits M.J., Kleibeuker J.H., et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 91 1 (2003) 74-80
48. Lindor N.M., Petersen G.M., Hadley D.W., et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296 12 (2006) 1507-1517
49. Schmeler K.M., Lynch H.T., Chen L.M., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354 3 (2006) 261-269
50. Aarnio M., Sankila R., Pukkala E., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81 2 (1999) 214-218